Long term management of childhood atopic dermatitis with calcineurin inhibitors;Langzeitmanagement des atopischen ekzems bei kindern mit calcineurininhibitoren

Hautarzt

Volumn 54, Issue 5, 2003, Pages 418-423

  Thaci D ^a,b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Atopic dermatitis; Calcineurin inhibitors; Long term management; Pimecrolimus; Tacrolimus

Indexed keywords

CALCINEURIN INHIBITOR; PIMECROLIMUS; TACROLIMUS;

ARTICLE; ATOPIC DERMATITIS; CHILD; CHILDHOOD DISEASE; CREAM; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INFANT; INFANT DISEASE; LONG TERM CARE; OINTMENT; TREATMENT OUTCOME;

EID: 0038170607     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-003-0524-3     Document Type: Article

References (26)

1. Schultz LF, Diepgen T, Svensson A (1996) The occurrence of atopic dermatitis in North Europe: an international questionnaire study. J Am Acad Dermatol 34:760-764
2. Williams H, Robertson C, Stewart A et al. (1999) Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Children. J Allergy Clin Immunol 103:125-138
3. Raimer SS (2000) Managing pediatric atopic dermatitis. Clin Pediatr 39:1-14
4. Drake L, Dinehart SM, Farmer ER et al.(1996) Guidelines of care for the use of topical glucocorticosteroids J Am Acad Dermatol 35:615-619
5. Charman C, Morris AD, Williams HC (2000) Topical corticosteroid phobia in patients with atopic dermatitis. Br J Dermatol 142:931-936
6. Stuetz A, Grassberger M, Meingassner JG (2001) Pimecrolimus (Elidel, SDZ ASM 981) - preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 20:233-241
7. Cheer SM, Plosker GL (2001) Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis. Am J Clin Dermatol 2:389-406
8. Queille-Roussel C Paul C, Duteil L et al.(2001) The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for four weeks: a randomised, double-blind controlled study. Br J Dermatol 144:507-513
9. Reitamo S, Rissanen J, Remitz A et al. (1998) Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 111:396-398
10. Harper J (2002) Tacrolimus ointment 0,03% shows minimal systemic absorbtion in paediatric patients with atopic dermatitis. JEADV 16 [Suppl I]:136 (Abstract)
11. Harper J, Lakhanpaul M, Wahn U et al. (2001) Pimecrolimus (Elidel®, SDZ ASM 981) cream 1% blood levels are consistently low in children with extensive atopic eczema. JEADV 15 [Suppl 2]:109
12. Paller A, Eichenfield LF, Leung DY et al. (2001) A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 44:S47-S57
13. Ruzicka T, Bieber T, Schopf E et al. (1997) A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 337:816-821
14. Reitamo S, Van Leent EJM, Ho V et al. (2002) Efficacy and safety of tacrolimus ointment compared with hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 109:S39-546
15. Harper J, Green A, Scott G et al. (2001) First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 144:781-787
16. Eichenfield LF, Lucky AW, Boguniewicz M et al. (2002) Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of atopic dermatitis in children and adolescents. J Am Acad Dermatol 46:495-504
17. Drake L, Prendergast M, Maher R et al. (2001) The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 44 [1 Suppl]:S65-72
18. Whalley D, Huels J, McKenna SP, van Assche D (in press) The benefit of pimecrolimus (Elidel, SDZ ASM 981) on quality of life in the treatment of paediatric atopic dermatitis. Pediatrics 2003
19. Kang S, Lucky AW, Pariser D et al. (2001) Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 44:S58-S64
20. Paller AS (2002) Long-term safety of topically applied tacrolimus ointment in pediatric patients 2-15 years of age with atopic dermatitis. 60th Annual Meeting of the AAD, New Orleans, LA: Poster 104
21. Remitz A, Kyllonen H, Granlund H, Reitamo S (2001) Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol 107:196-197
22. Lübbe J, Pournaras CC, Saurat JH (2000) Eczema herpeticum during treatment of atopic dermatitis with 0,1% tacrolimus ointment. Dermatology 201:249-251
23. Hanifin J, Ho V, Kaufmann R et al. (2002) Pimecrolimus (SDZ ASM 981) cream: good tolerability in paediatric patients (conference abstract). 20th World Congress of Dermatology, July 1-5, 2002, Paris. Ann Dermatol Venereol 129:1S411
24. Ho V, Halbert A, Takoaka R et al. (2001) Pimecrolimus (Elidel®, SDZ ASM 981) Cream 1% is effective and safe in infants aged 3-23 months with atopic dermatitis (conference abstract). JEADV 15 [Suppl 2]:110
25. Kapp A, Papp K, Bingham A et al. (2002). Efficacy and safety of pimecrolimus cream, a novel non-steroid anti-inflammatory, in long-term management of atopic dermatitis in infants. J Allergy Clin Immunol 110:277-284
26. Wahn U, Bos JD, Goodfield M et al. (2002) Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 110:e2